Altimmune, Inc. (ALT)
Altimmune, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Gaithersburg, MD, US. The stock last traded at $3.00, down 1.64% on the session, giving a market capitalisation of $583.4M. On trailing twelve-month figures it carries a trailing P/E of -3.90, a net margin of -119168.8%. Its beta of 0.17 implies it has historically moved less than the broad market.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Altimmune, Inc. is most often compared with the following Healthcare names: